TOP PHARMACEUTICAL COMPANIES BY REVENUES 2023
JOHNSON AND JOHNSON
Johnson and Johnson reported Q1 revenues for 2023. The company reported revenues of $24.7 billion, an increase of 5.6% versus 2022 ($23.4 billion). The consumer health revenues were $3.8 billion, pharmaceutical revenues were $13.4 billion, and MedTech revenues were $7.5 billion.
Also read: Top pharmaceutical companies of 2022
The best-selling products are Stelara ($2.4 billion), Darzalex ($2.2 billion), Imbruvica ($0.83 billion), and Tremfya ($0.64 billion).
Pfizer reported a 29% drop in revenues for the first quarter. Comirnaty revenues dropped by 75%, resulting in $3.0 billion, while Paxlovid revenues reached $4.0 billion. Other best-selling drugs included Eliquis ($1.9 billion), the Prevnar family ($1.6 billion), and Ibrance ($1.1 billion).
Roche reported a drop in revenues by 3% at CER. However, the pharmaceutical division saw an increase in revenues by 9%, while there was a drop of 28% in the diagnostics division.
Also read: HAS assessment outcomes
The pharmaceutical division revenues were $13.2 billion. The best-selling products were Ocrevus ($1.8 billion), Perjeta ($1.2 billion), Hemlibra ($1.2 billion), Tecentriq ($1.0 billion), and Actemra ($0.8 billion).
Novartis reported revenues of $13.0 billion in the first quarter of 2023, with a growth of 8% at constant currency. The innovative medicines revenues increased by 7%, and Sandoz division revenues increased by 8%.
The company's best-selling products were Entresto ($1.4 billion) and Cosentyx ($1.1 billion).
Merck's pharmaceutical segment experienced a decrease of 10%, with first-quarter revenues at $12.7 billion due to the reduced demand for Lagevrio. However, Keytruda revenues grew at an impressive 20%, generating $5.8 billion in reven